NCT01791972 - Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions

Exercise-Induced Bronchoconstriction (EIB)

Interventions

DRUG

Albuterol Spiromax

Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).

DRUG

Placebo Spiromax

Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.

Trial Locations (6)

Unknown

Teva Investigational Site 10557, San Diego

Teva Investigational Site 10555, Denver

Teva Investigational Site 10558, Denver

Teva Investigational Site 10559, Wheaton

Teva Investigational Site 10560, North Dartmouth

Teva Investigational Site 10556, Raleigh

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY